🇺🇸 SECMoleculin Biotech, Inc.Doubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 21:29:32·⟳ 抓取 21:30:04 +32s·⚡ 决策 10-16 21:31:08 +1m04s·11.3 天前
Moleculin Biotech 仅提交投资者演示文稿的例行 8-K（Item 7.01），无新增实质性临床或财务信息
这是一份 Item 7.01 例行 Reg FD 备案，唯一动作是把日期为当日的公司投资者演示文稿放上网站；正文与附件不含临床数据、监管进展、融资、合同或指引等新信息，属典型程序性/营销材料披露，无预期差也无可验证催化，不构成交易。
📄 原文Moleculin Biotech, Inc.↗ 原文
----- mbrx20261015_8k.htm ----- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURREN…
不做 Moleculin Biotech, Inc.（MBRX.US）
8-K 仅为 Item 7.01 例行 Reg FD 披露（投资者演示文稿挂网，furnished 非 filed），无新增临床、财务、合同或公司行动信息，无预期差与可交易 edge；除非演示文稿实际包含未公开关键数据并被市场确认，否则不参与。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Moleculin 的 8-K 只是把常规投资者演示文稿挂网（Item 7.01，furnished 非 filed），无新增临床、财务或公司行动事实；没有可交易的增量信息，回避。
🔎 新鲜度:最早出现 2026-10-16 · 扩散 low · price-in 风险 low ↗
主要风险
- Exhibit 99.1 实际演示文稿可能含管线更新（如 annamycin / WP1066 临床进展），若公司网站版本含此前未公布的关键数据，则本条 AVOID 需重估
先例如何影响了这次决策
对本次决策的影响:未改变结论；程序性 Reg FD 披露按无 edge 处理。
方向:无可对照先例；例行 Item 7.01 演示文稿挂网本身通常不构成事件研究级催化，未做外部先例检索。
涨幅量级:不适用：无增量事实，无幅度可校准。
形态:无
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 14 ms
{"result": "search_processed_events:agent query=`mbrx reg fd 7.01 投资者演示文稿 2026 | moleculin biotech corporate presentation exhibit 99.1 october 16 2026 | moleculin biotech mbrx investor presentation october 2026 8-k`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回
原文全文
展开原文 · 3,365 字
----- mbrx20261015_8k.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
October 16, 2026
MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-37758
47-4671997
(State or Other Jurisdiction of
Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification No.)
5300 Memorial Drive
,
Suite 950
,
Houston
,
TX
77007
(Address of principal executive offices and zip code)
(
713
)
300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock
, par value $.001 per share
MBRX
The
NASDAQ
Stock Market LLC
Item 7.01
Regulation FD Disclosure
On October 16, 2026, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit No.
Description
99.1
Investor Presentation dated October 16, 2026
104
Cover page Interactive Data File (formatted as Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOLECULIN BIOTECH, INC.
Date:
October 16, 2026
By:
/s/ Jonathan P. Foster
Jonathan P. Foster
----- ex_1026331_source.htm -----
EX-99.1
2
ex_1026331_source.htm
EXHIBIT 99.1
ex_1026331_source.htm
Exhibit 99.1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
October 16, 2026
MOLECULIN BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-37758
47-4671997
(State or Other Jurisdiction of
Incorporation or Organization)
(Commission File No.)
(I.R.S. Employer Identification No.)
5300 Memorial Drive
,
Suite 950
,
Houston
,
TX
77007
(Address of principal executive offices and zip code)
(
713
)
300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol (s)
Name of each exchange on which registered
Common Stock
, par value $.001 per share
MBRX
The
NASDAQ
Stock Market LLC
Item 7.01
Regulation FD Disclosure
On October 16, 2026, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit No.
Description
99.1
Investor Presentation dated October 16, 2026
104
Cover page Interactive Data File (formatted as Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOLECULIN BIOTECH, INC.
Date:
October 16, 2026
By:
/s/ Jonathan P. Foster
Jonathan P. Foster
----- ex_1026331_source.htm -----
EX-99.1
2
ex_1026331_source.htm
EXHIBIT 99.1
ex_1026331_source.htm
Exhibit 99.1
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
8ecdd2ec3c· 2026-10-16 21:31 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前